Search Results for keywords:"drug market competition"

Search Results: keywords:"drug market competition"

S. 1096 — To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
💰
March 24, 2025
Status:Introduced in Senate
Congress:119
Words:4,454
S. 1096, titled the “Preserve Access to Affordable Generics and Biosimilars Act,” aims to stop brand name and generic drug companies from making deals that delay cheaper generic drugs from entering the market. The bill also addresses similar deals regarding biological medicines and their more...
Simple Explanation
This bill wants to make sure that brand name and cheaper generic drug companies, as well as makers of biological medicines, play fair and don't make secret deals that keep cheaper drugs out of stores. It's like stopping some companies from paying others to keep kids from having more choices in their toy store.
S. 1096 — To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
💰
April 10, 2025
Status:Reported to Senate
Congress:119
Words:8,826
The bill S. 1096, also known as the "Preserve Access to Affordable Generics and Biosimilars Act," aims to prevent brand-name drug companies from paying generic drug companies to delay their cheaper drugs from entering the market. This tactic, known as "reverse payment"...
Simple Explanation
The bill wants to stop big drug companies from paying to keep cheaper, similar drugs away so people can get them sooner and pay less. If companies break the rules, they might get in trouble with the people in charge.
H. R. 1051 — To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
February 06, 2025
Status:Introduced in House
Congress:119
Words:1,129
H.R. 1051 seeks to amend the Federal Food, Drug, and Cosmetic Act to address the approval process for generic drug applications. If the first applicant fails to start selling their drug within a set time, a later applicant could get approval under certain conditions, even if...
Simple Explanation
H.R. 1051 explains that if a company is too slow to sell a new medicine, another company might be allowed to start selling it instead, so people can get their medicines more quickly.

Showing 1 to 3 of 3 results